Back to Journals » Cancer Management and Research » Targeting Cancer Stem Cells to Overcome Therapy Resistance: Mechanisms, Biomarkers, and Clinical Translation
Cancer Management and Research
- View all (5187)
- Volume 18, 2026 (153)
- Volume 17, 2025 (276)
- Volume 16, 2024 (164)
- Volume 15, 2023 (153)
- Volume 14, 2022 (330)
- Volume 13, 2021 (890)
- Volume 12, 2020 (1256)
- Volume 11, 2019 (969)
- Volume 10, 2018 (645)
- Volume 9, 2017 (89)
- Volume 8, 2016 (17)
- Volume 7, 2015 (33)
- Volume 6, 2014 (43)
- Volume 5, 2013 (41)
- Volume 4, 2012 (47)
- Volume 3, 2011 (32)
- Volume 2, 2010 (32)
- Volume 1, 2009 (17)
Journal Articles:
- Targeting Cancer Stem Cells to Overcome Therapy Resistance: Mechanisms, Biomarkers, and Clinical Translation (1)
- Self Screening for Cancer: Promises and Pitfalls (1)
- Immune Effector Cells for Cancer Therapy – CAR-T and beyond (1)
- Defining Genetic Contributors to Cancer Risk (1)
- The Cancer Treatment Revolution and the Threat to Equitable Global Medicines Access (2)
- Establishing New Standards in Neuroendocrine Tumors: Raising the Bar to Set New Benchmarks (1)
Targeting Cancer Stem Cells to Overcome Therapy Resistance: Mechanisms, Biomarkers, and Clinical Translation
Cancer stem cells (CSCs) are a therapy-resistant subpopulation that drives tumor initiation, progression, metastasis, and recurrence. Their capacity for self-renewal, plasticity, and adaptation underpins resistance to chemotherapy, radiotherapy, and immunotherapy, making them a central obstacle to long-term therapeutic success. Eradicating CSCs is thus recognized as a critical goal in improving long-term patient survival.
Hippo-YAP/TAZ Signaling in Hematological Malignancies: Molecular Mechanisms, Pathway Crosstalk and Therapeutic Potential
Jiang W, Zhu C, Xu L, Ma N
Cancer Management and Research 2026, 18:618762
Published Date: 7 July 2026